Ezrin Peptide 1 for Post-COVID-19 Syndrome Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an urgent need for effective treatments for post-COVID-19 syndrome, as current measures such as vaccination do not guarantee complete protection against SARS-CoV-2 infection, and the development of new therapeutics may take several months to a year, leaving a gap in managing long-term symptoms affecting multiple organ systems.
Innovation Solution
Ezrin peptide 1 and its analogues, administered alone or in combination with pharmaceutically acceptable carriers, are used to treat and prevent post-COVID-19 syndrome by reducing inflammatory cytokine production and inducing anti-viral effects, thereby improving or curing symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If vaccination is used to prevent SARS-CoV-2 infection, then protection against infection is improved, but complete protection is not guaranteed and gaps remain in managing long-term symptoms
Solution Approach 1:
The patent segments the protection approach into two distinct components: vaccination for acute infection prevention and Ezrin peptide treatment for post-COVID-19 syndrome management. This segmentation allows each component to address its specific function optimally, with the peptide targeting the persistent inflammatory and fibrotic processes that vaccines do not address.
Solution Approach 2:
The patent applies preliminary action by administering Ezrin peptide treatment during the acute COVID-19 phase to prevent the development of post-COVID-19 syndrome. This proactive approach addresses the harmful fibrotic and inflammatory processes before they establish long-term damage, rather than waiting for chronic symptoms to manifest.
2Reliability
If new therapeutics are developed to treat post-COVID-19 syndrome, then treatment effectiveness is improved, but development time takes several months to a year
Solution Approach 1:
The patent leverages the existing, well-characterized Ezrin peptide (originally developed for HIV and hepatitis C) and adapts it for post-COVID-19 treatment. This copying approach allows immediate utilization of a proven safe peptide with known pharmacological properties, avoiding the lengthy development and safety testing required for entirely new therapeutics.
Solution Approach 2:
The patent modifies the application parameters of the Ezrin peptide for its new indication in post-COVID-19 syndrome, including dosage regimens (e.g., 0.5-5 mg/day), administration routes, and treatment duration. These parameter adjustments enable rapid adaptation of an existing molecule to a new therapeutic context without requiring de novo development.
3Reliability
If Ezrin peptide 1 is administered to treat post-COVID-19 syndrome, then symptoms are improved or cured, but the mechanism involves complex immunomodulation and anti-fibrotic effects
Solution Approach 1:
The Ezrin peptide exhibits multi-functionality by simultaneously performing immunomodulation (reducing inflammatory cytokines like TNF-α, IL-6, IL-1β), anti-fibrotic effects (inhibiting TGF-β signaling and collagen deposition), and anti-viral activities. This universal action against multiple pathological pathways simplifies the therapeutic approach compared to using multiple separate agents.
Solution Approach 2:
The patent utilizes the peptide's ability to self-regulate complex immunological and fibrotic processes through its binding to ezrin protein, which acts as a scaffold in cellular signaling. The peptide restores normal ezrin function, allowing the body's own regulatory mechanisms to resolve inflammation and fibrosis without requiring complex external control systems.
Data Source
AI summary
The present invention concerns Ezrin peptide 1 for use in a method of treating post COVID-19 syndrome.